Cyclin D1b protein expression in breast cancer is independent of cyclin D1a and associated with poor disease outcome

Oncogene

Volumn 28, Issue 15, 2009, Pages 1812-1820

  Millar, E K A ^a,b   Dean, J L ^c,d   McNeil, C M ^a   O'Toole, S A ^a   Henshall, S M ^a   Tran, T ^c,d   Lin, J ^c,d   Quong, A ^c   Comstock, C E S ^c,d   Witkiewicz, A ^c,d   Musgrove, E A ^a   Rui, H ^c,d   Lemarchand, L ^e   Setiawan, V W ^f   Haiman, C A ^f   Knudsen, K E ^c,d   Sutherland, R L ^a   Knudsen, E S ^c,d  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b ST GEORGE HOSPITAL   (Australia)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

^e UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Breast cancer; Cyclin D1b; Estrogen receptor; Polymorphism; Prognosis

Indexed keywords

BIOLOGICAL MARKER; CYCLIN D1; CYCLIN D1A; CYCLIN D1B; ESTROGEN RECEPTOR; KI 67 ANTIGEN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER RISK; CASE CONTROL STUDY; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DISTANT METASTASIS; DNA POLYMORPHISM; ETHNICITY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SECRETION; RECEPTOR UPREGULATION; RECURRENT DISEASE; RISK FACTOR;

BREAST NEOPLASMS; CYCLIN D1; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; POLYMORPHISM, GENETIC; PROGNOSIS; PROTEIN ISOFORMS; RECEPTORS, ESTROGEN;

EID: 65049084565     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2009.13     Document Type: Article

References (44)

1. Arnold A, Papanikolaou A. (2005). Cyclin D1 in breast cancer pathogenesis. J Clin Oncol 23: 4215-4224.
2. Bala S, Peltomaki P. (2001). Cyclin D1 as a genetic modifier in hereditary nonpolyposis colorectal cancer. Cancer Res 61: 6042-6045.
3. Barnes DM, Gillett CE. (1998). Cyclin D1 in breast cancer. Breast Cancer Res Treat 52: 1-15.
4. Batsche E, Yaniv M, Muchardt C. (2006). The human SWI/SNF subunit Brm is a regulator of alternative splicing. Nat Struct Mol Biol 13: 22-29.
5. Betticher DC, Thatcher N, Altermatt HJ, Hoban P, Ryder WD, Heighway J. (1995). Alternate splicing produces a novel cyclin D1 transcript. Oncogene 11: 1005-1011.
6. Blais A, Dynlacht BD. (2007). E2F-associated chromatin modifiers and cell cycle control. Curr Opin Cell Biol 19: 658-662.
7. Buckley MF, Sweeney KJ, Hamilton JA, Sini RL, Manning DL, Nicholson RI et al (1993). Expression and amplification of cyclin genes in human breast cancer. Oncogene 8: 2127-2133.
8. Burd CJ, Petre CE, Morey LM, Wang Y. Revelo MP, Haiman CA et al. (2006). Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation. Proc Natl Acad Sci USA 103: 2190-2195.
9. Carrere N, Belaud-Rotureau MA, Dubus P, Parrens M, de Mascarel A, Merlio JP. (2005). The relative levels of cyclin D1a and D1b alternative transcripts in mantle cell lymphoma may depend more on sample origin than on CCND1 polymorphism. Haematologica 90: 854-856.
10. Ceschi M, Sun CL, Van Den Berg D, Koh WP, Yu MC, Probst-Hensch N. (2005). The effect of cyclin D1 (CCND1) G870A-polymorphism on breast cancer risk is modified by oxidative stress among Chinese women in Singapore. Carcinogenesis 26: 1457-1464.
11. Cobrinik D. (2005). Pocket proteins and cell cycle control. Oncogene 24: 2796-2809.
12. Comstock CES, Augello MA, Pe Benito R, Karch J, Tran TH, Utama FE et al, (2009). Cyclin D1 splice variants: polymorphism., risk, and isoform specific regulation in prostate cancer. Clin Cancer Res (submitted).
13. Diehl JA. (2002). Cycling to cancer with cyclin Dl. Cancer Biol Ther 1: 226-231.
14. Dolled-Filhart M, McCabe A, Giltnane J, Cregger M, Camp RL, Rimm DL. (2006). Quantitative in situ analysis of beta-catenin expression in breast cancer shows decreased expression is associated with poor outcome. Cancer Res 66: 5487-5494.
15. Gillett C, Fantl V, Smith R, Fisher C, Bartek J, Dickson C et al. (1994). Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 54: 1812-1817.
16. Gillett C, Smith P, Gregory W, Richards M, Millis R, Peters G et al. (1996). Cyclin D1 and prognosis in human breast cancer. Int J Cancer 69: 92-99.
17. Gupta VK, Feber A, Xi L, Pennathur A, Wu M, Luketich JD et al. (2008). Association between CCND1 G/A870 polymorphism, allele-specific amplification, cyclin D1 expression, and survival in esophageal and lung carcinoma. Clin Cancer Res 14: 7804-7812.
18. Holley SL, Heighway J, Hoban PR. (2005). Induced expression of human CCND1 alternative transcripts in mouse Cyl-1 knockout fibroblasts highlights functional differences. Int J Cancer 114: 364-370.
19. Holley SL, Parkes G, Matthias C, Bockmuhl U, Jahnke V, Leder K et al. (2001). Cyclin D1 polymorphism and expression in patients with squamous cell carcinoma of the head and neck. Am J Pathol 159: 1917-1924.
20. Iaquinta PJ, Lees JA. (2007). Life and death decisions by the E2F transcription factors. Curr Opin Cell Biol 19: 649-657.
21. Jirstrom. K, Stendahl M, Ryden L, Kronblad A, Bendahl PO, Stal O et al. (2005). Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification. Cancer Res 65: 8009-8016.
22. Knudsen ES, Knudsen KE. (2006). Retinoblastoma tumor suppressor: where cancer meets the cell cycle. Exp Biol Med (Maywood) 231: 1271-1281.
23. Knudsen KE. (2006). The cyclin D1b splice variant: an old oncogene learns new tricks. Cell Div 1:15.
24. Knudsen KE, Diehl JA, Haiman CA, Knudsen ES. (2006). Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene 25: 1620-1628.
25. Krieger S, Gauduchon J, Roussel M, Troussard X, Sola B. (2006). Relevance of cyclin D1b expression and CCND1 polymorphism in the pathogenesis of multiple myeloma and mantle cell lymphoma. BMC Cancer 6: 238.
26. Krippl P, Langsenlehner U, Renner W, Yazdani-Biuki B, Wolf G, Wascher TC et al. (2003). The 870G > A polymorphism of the cyclin D1 gene is not associated with breast cancer. Breast Cancer Res Treat 82: 165-168.
27. Lu F, Gladden AB, Diehl JA. (2003). An alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene. Cancer Res 63: 7056-7061.
28. Malumbres M, Barbacid M. (2001). To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 1: 222-231.
29. Marzec M, Kasprzycka M, Lai R, Gladden AB, Wlodarski P, Tomczak E et al. (2006). Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK.4 kinase activity. Blood 108: 1744-1750.
30. Matthias C, Branigan K, Jahnke V, Leder K, Haas J, Heighway J et al. (1998). Polymorphism within the cyclin D1 gene is associated with prognosis in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 4: 2411-2418.
31. Naidu R, Yip CH, Taib NA. (2008). Polymorphisms of HER2 Ile655Val and cyclin D1 (CCND1) G870A are not associated with breast cancer risk but polymorphic allele of HER2 is associated with nodal metastases. Neoplasma 55: 87-95.
32. Pabalan N, Bapat B, Sung L, Jarjanazi H, Francisco-Pabalan O, Ozcelik H. (2008). Cyclin D1 Pro241Pro (CCND1-G870A) polymorphism is associated with increased cancer risk in human populations: a meta-analysis. Cancer Epidemiol Biomarkers Prev 17:2773-2781.
33. Roy PG, Thompson AM. (2006). Cyclin D1 and breast cancer. Breast 15: 718-727.
34. Rudas M, Lehnert M, Huynh A, Jakesz R, Singer C, Lax S et al. (2008). Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy. Clin Cancer Res 14: 1767-1774.
35. Sanchez G, Bittencourt D, Laud K, Barbier J, Delattre O, Auboeuf D et al. (2008). Alteration of cyclin Dl transcript elongation by a mutated transcription factor up-regulates the oncogenic D1b splice isoform in cancer. Proc Natl Acad Sci USA 105: 6004-6009.
36. Shu XO, Moore DB, Cai Q, Cheng J, Wen W, Pierce L et al. (2005). Association of cyclin D1 genotype with breast cancer risk and survival. Cancer Epidemiol Biomarkers Prev 14: 91-97.
37. Sicinski P, Donaher JL, Parker SB, Li T, Fazeli A, Gardner H et al. (1995). Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell 82: 621-630.
38. Solomon DA, Wang Y, Fox SR, Lambeck TC, Giesting S, Lan Z et al. (2003). Cyclin D1 splice variants. Differential effects on localization, RB phosphorylation, and cellular transformation. J Biol Chem 278: 30339-30347.
39. Spruck C, Sun D, Fiegl H, Marth C, Miueller-Holzner E, Goebel G et al. (2006). Detection of low molecular weight derivatives of cyclin E1 is a function of cyclin E1 protein levels in breast cancer. Cancer Res 66: 7355-7360.
40. Sutherland RL, Musgrove EA. (2004). Cyclins and breast cancer. J Mammary Gland Biol Neoplasia 9: 95-104.
41. Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, Schmidt EV. (1994). Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 369: 669-671.
42. Wang Y, Dean JL, Millar EK, Tran TH, McNeil CM, Burd CJ et al. (2008). Cyclin D1b is aberrantly regulated in response to therapeutic challenge and promotes resistance to estrogen antagonists. Cancer Res 68: 5628-5638.
43. Yu CP, Yu JC, Sun CA, Tzao C, Ho JY, Yen AM. (2008). Tumor susceptibility and prognosis of breast cancer associated with the G870.A polymorphism of CCND1. Breast Cancer Res Treat 107: 95-102.
44. Yu Q, Geng Y, Sicinski P. (2001). Specific protection against breast cancers by cyclin D1 ablation. Nature 411: 1017-1021.